Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination

Development of T cell-directed immune checkpoint inhibitors (ICI) has revolutionized metastatic melanoma (MM) therapy, but <50% of treated patients experience durable responses. This phase I trial (NCT01946373) investigates the safety/feasibility of tumor-infiltrating lymphocyte (TIL) adoptive ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Lövgren, Tanja, Wolodarski, Maria, Wickström, Stina, Edbäck, Ulrika, Wallin, Mette, Martell, Eva, Markland, Katrin, Blomberg, Pontus, Nyström, Maria, Lundqvist, Andreas, Jacobsson, Hans, Ullenhag, Gustav, Ljungman, Per, Hansson, Johan, Masucci, Giuseppe, Tell, Roger, Poschke, Isabel, Adamson, Lars, Mattsson, Jonas, Kiessling, Rolf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458624/
https://www.ncbi.nlm.nih.gov/pubmed/32923156
http://dx.doi.org/10.1080/2162402X.2020.1792058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458624/
https://www.ncbi.nlm.nih.gov/pubmed/32923156
http://dx.doi.org/10.1080/2162402X.2020.1792058

Ejemplares similares